IL2 and osteosarcoma: The addition of immunomodulatory cytokines such as IL2, IL15, and liposomal-muramyl tripeptide phosphatidylethanolamine might induce T cell proliferation and differentiation to improve the survival outcomes of osteosarcoma patients, but the evidence is insufficient.